Aguilar LMV, Portillo SA, Avila RO, Castro RE, Escobar RD

Language: Spanish
References: 22
Page: 12-16
PDF size: 55.77 Kb.

ABSTRACT

This paper analyzes effectiveness between oxybutynin compare with placebo for hyperactive bladder treatment in spinal cord injury patients. Fifteen total or partial lesion in both spinal cord injury and hyperactive bladder patients were studied. Catheterism was performed each 4.6 or 8 hours per day. Oxybutynin or placebo were taken in a daily 15 mg doses. Both were reduced depending patient response during three weeks. Urinary volume during catheterism and mictions number were registered. Seven patients conformed the Control Group and 8 patients conformed the Experimental Group. Patients in experimental group showed better response than control group. In conclusion patients who received oxybutynin decrease number of daily catheterism procedures and presented an increment in the bladder capacity.

REFERENCES

1. Mazaira J et al. Epidemiología de la lesión medular y otros aspectos. Rehabilitación (Madrid) 1998; 32: 365-72.

2. Sember M, Cibeira B, Colinas R. Manual de Neurourología. Buenos Aires, El Ateneo, 1990: 129.

3. Boisson J. Incidence of acute care complications in vertebral column fracture with and without spinal cord injury. Spine 1995; 20(10): 1136-46.

4. Lightner D. Contemporary urologic management of patients with spinal cord injury. Mayo Clinic Proceedings 1998; 73(5): 434-8.

5. DeLisa J. Rehabilitation medicine. Principles and Practice. 3ª. Ed. Philadelphia. Lippincott-Raven 1998: 1073-1106.

6. Ganagho E, Schmnidtr R. Urología general de Smith. 9ª Ed. México, Manual moderno, 1989: 616.

7. Seuber M, Cibeira J. Manual de Neurourología. Argentina, El Ateneo, 1990: 122.

8. Wheeler J, Walter J, Acute urologic management of neurogenic bladder in patients with spinal cord injury. Urol Clin N Am 1993; 20: 283-89.

9. Karen L, Douglas A. Bladder dysfunction and management in multiple sclerosis. Mayo Clinic Proceedings 1997; 72: 1176-83.

10. Amarenco G, Adba MA, Kerdraon J. Value of intravesically instilled oxybutynin in refractory bladder hyperactivity. Study of 15 cases. Progres en Urologie 1992; 2(4): 660-3.

11. Hehir M, Fitzpatrick JM. Oxybutynin and the prevention of urinary incontinence in spine bifida. European Urology 1985; 11(4): 254-6.

12. Hafferkamp et al. Dosage escalation of intravesical oxybutynin in the treatment of neurogenic bladder patients. Spinal cord 2000; 38(4): 250-4.

13. Amark P, Eksborg S. Pharmacokinetics and effects of intravesical oxybutynin on the paediatric neurogenic bladder. Br J Urol 1998; 82: 859-64.

14. Weesw DL, Roskamp DA. Intravesical oxybutynin chloride: experience with 42 patients. Urology 1993; 41(6): 527-30.

15. Szonyi GC, Ding YY. Oxybutynin with bladder retraining for detrusor instability in elderly people: a randomized controlled trial. Age Ageing 1995; 24(4): 287-91.

16. Nilsson CG, Lukkari E. Comparison of a 10 mg controlled release oxybutynin tablet with a 5 mg oxybutynin tablet in urge incontinent patients. Neurourol Urodyn 1997; 16(6): 533-42.

17. Yavuzer G, Gok H. Compliance with bladder management in spinal cord injury patients. Spinal cord 2000; 38: 762-65.

18. Ouslander J. Pharmacokinetics and clinical effects of oxybutynin in geriatric Patients. J Urol 1988; 140: 47-50 Amark P, Eksborg S. Pharmacokinetics and effects of intravesical oxybutynin on the paediatric neurogenic bladder. Br J Urol 1998; 82: 859-64.

19. Yarker Y, Goa K. Oxybutynin review of its pharmacodynamic and pharmacokinetic properties and its therapeutic use in detrusor instability. Drugs & aging 1995; 6(3): 243-62.

20. Douchamps J, Derenne F. Pharmacokinetics and clinical effects of oxybutynin on the paediatric patients. J Urol 1988; 140: 47-49.

21. Kirkali Z. The use of oxybutynin in urological practice. Int Urol Nephrol 1987; 19: 385-91.

22. Winkler HA, Sand PK. Treatment of detrusor instability with oxybutynin rectal suppositories. Int Urogynecol J Pelvic Floor dysfunct 1998; 9(2): 100-2.